专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2005292087A Antibody to 5'-deoxy-5'-methylthioadenosine 审中-公开
标题翻译： 5'-去氧-5'-甲氧基苯并OS嗪抗体
公开(公告)号：JP2005292087A
公开(公告)日：2005-10-20
申请号：JP2004111373
申请日：2004-04-05
申请人： Quark Biotech Inc , Shionogi & Co Ltd , クアーク・バイオテック・インコーポレイテッド , 塩野義製薬株式会社
发明人： NUMATA YOSHITO , ENOMOTO KOJI , YAMAUCHI AKIRA
IPC分类号： G01N33/53 , C07H19/16 , C07K16/00 , C07K16/44 , C07K17/06 , C12N5/10 , C12N5/12 , C12N5/20 , C12N15/02 , C12P21/08 , G01N21/78 , G01N33/15 , G01N33/50 , G01N33/531 , G01N33/533 , G01N33/534 , G01N33/535 , G01N33/543 , G01N33/577
CPC分类号： C07K16/44 , C07K2317/92
摘要： PROBLEM TO BE SOLVED: To solve the problem that conventional arts have no antibody, especially monoclonal antibody which specifically recognizes 5'-deoxy-5'-methylthioadenosine (MTA), or no assay method which enables the measurement of an activity of spermidine synthase with high sensitivity. SOLUTION: A new immunogen is produced and used, whereby an antibody having a very high specificity can be produced. Furthermore, the spermidine synthase can be measured with the high sensitivity by using the antibody. COPYRIGHT: (C)2006,JPO&NCIPI
摘要翻译：解决问题：为了解决现有技术中没有抗体，特别是特异性识别5'-脱氧-5'-甲基硫代腺苷（MTA）的单克隆抗体的问题，或者没有能够测定活性的测定方法亚精胺合酶高灵敏度。解决方案：产生和使用新的免疫原，从而可以产生具有非常高的特异性的抗体。此外，可以通过使用抗体以高灵敏度测量亚精胺合酶。版权所有（C）2006，JPO＆NCIPI

2. 发明申请

US20030104973A1 Hypoxia-regulated genes 审中-公开
标题翻译：低氧调控基因
公开(公告)号：US20030104973A1
公开(公告)日：2003-06-05
申请号：US10091333
申请日：2002-03-06
申请人： Quark Biotech, Inc.
发明人： Paz Einat , Rami Skaliter
IPC分类号： A61K031/00 , C07H021/04 , C07K014/47 , C07K016/40
CPC分类号： C07K14/4702 , A61K38/00 , A61K48/00 , C07K14/47 , C07K14/4747
摘要： According to the present invention, purified, isolated and cloned nucleic acid polynucleotide encoding hypoxia-regulating genes and the proteins thereof and antibodies directed against the proteins which have sequences as set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 are provided. The present invention further provides transgenic animals and cell lines as well as knock-out organisms of these sequences. The present invention further provides methods of regulating angiogenesis or apoptosis or regulating response to ischemic or hypoxic conditions in a patient in need of such treatment. The present invention also provides a method of diagnosing the presence of ischemia in a patient including the steps of analyzing a bodily fluid or tissue sample from the patient for the presence, or gene product, of at least one expressed gene (up-regulated) as set forth in the group comprising SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and SEQ ID NO:6 and where ischemia is determined if the up-regulated gene or gene product is ascertained.
摘要翻译：根据本发明，编码缺氧调节基因的纯化，分离和克隆的核酸多核苷酸及其蛋白质和针对具有SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：2所示序列的蛋白质的抗体提供了NO：3，SEQ ID NO：4，SEQ ID NO：5和SEQ ID NO：6。本发明进一步提供这些序列的转基因动物和细胞系以及敲除生物体。本发明还提供了在需要这种治疗的患者中调节血管发生或凋亡或调节对缺血或缺氧条件的反应的方法。本发明还提供一种诊断患者局部缺血的方法，包括以下步骤：从患者体内分析至少一种表达基因（上调）的存在或基因产物的体液或组织样品，作为如SEQ ID NO：2所示; SEQ ID NO：3; SEQ ID NO：4; SEQ ID NO：5; 和SEQ ID NO：6，并且如果确定上调基因或基因产物，则确定缺血。

3. 发明专利

TW200806325A RTP801抑制劑之醫療用途 THERAPEUTIC USES OF INHIBITORS OF RTP801 审中-公开
简体标题： RTP801抑制剂之医疗用途 THERAPEUTIC USES OF INHIBITORS OF RTP801
公开(公告)号：TW200806325A
公开(公告)日：2008-02-01
申请号：TW096102139
申请日：2007-01-19
申请人：夸克生技有限公司 QUARK BIOTECH, INC. , 奧圖真公司 ATUGEN AG
发明人：艾蓮那范斯坦 FEINSTEIN, ELENA , 拉米史卡利特 SKALITER, RAMI
IPC分类号： A61K
CPC分类号： C07K16/18 , A61K2039/505 , C07K14/4747 , C07K16/22 , C12N15/113 , C12N2310/14 , C12N2310/321 , C12N2310/3521
摘要：本發明提供在抑制RTP801基因及/或蛋白之基礎上用於治療微血管病症、眼病、呼吸病狀及聽力障礙之新穎分子、組合物、方法及用途。
简体摘要：本发明提供在抑制RTP801基因及/或蛋白之基础上用于治疗微血管病症、眼病、呼吸病状及听力障碍之新颖分子、组合物、方法及用途。

4. 发明申请

US20030124116A1 Hypoxia-regulated genes 有权
标题翻译：低氧调控基因
公开(公告)号：US20030124116A1
公开(公告)日：2003-07-03
申请号：US10325878
申请日：2002-12-23
申请人： Quark Biotech, Inc.
发明人： Paz Einat , Rami Skaliter
IPC分类号： A61K039/395 , C07K016/46
CPC分类号： C07K14/4747 , A61K38/00 , A61K48/00 , C07K14/47 , C07K14/4702
摘要： According to the present invention, purified, isolated and cloned nucleic acid polynucleotide encoding hypoxia-regulating genes and the proteins thereof and antibodies directed against the proteins which have sequences as set forth in SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5 and SEQ ID NO:6 are provided. The present invention further provides transgenic animals and cell lines as well as knock-out organisms of these sequences. The present invention further provides methods of regulating angiogenesis or apoptosis or regulating response to hypoxic conditions in a patient in need of such treatment. The present invention also provides a method of diagnosing the presence of ischemia in a patient including the steps of analyzing a bodily fluid or tissue sample from the patient for the presence or gene product of at least one expressed gene (up-regulated) as set forth in the group comprising SEQ ID NO:2; SEQ ID NO:3; SEQ ID NO:4; SEQ ID NO:5; and SEQ ID NO:6 and where ischemia is determined if the up-regulated gene or gene product is ascertained.
摘要翻译：根据本发明，编码缺氧调节基因的纯化，分离和克隆的核酸多核苷酸及其蛋白质和针对具有SEQ ID NO：1，SEQ ID NO：2，SEQ ID NO：2所示序列的蛋白质的抗体提供了NO：3，SEQ ID NO：4，SEQ ID NO：5和SEQ ID NO：6。本发明进一步提供这些序列的转基因动物和细胞系以及敲除生物体。本发明还提供了在需要这种治疗的患者中调节血管发生或凋亡或调节对缺氧条件的反应的方法。本发明还提供了一种诊断患者局部缺血的方法，包括以下步骤：从患者体内分析至少一种表达基因（上调）的存在或基因产物，如上所述在包含SEQ ID NO：2的组中; SEQ ID NO：3; SEQ ID NO：4; SEQ ID NO：5; 和SEQ ID NO：6，并且如果确定上调基因或基因产物，则确定缺血。

5. 发明申请

US20040229886A1 Inhibitors of spermidine synthase for the treatment of osteoarthritis and cartilage rehabilitation 审中-公开
标题翻译：亚精胺合酶抑制剂用于治疗骨关节炎和软骨康复
公开(公告)号：US20040229886A1
公开(公告)日：2004-11-18
申请号：US10786830
申请日：2004-02-24
申请人： Quark Biotech, Inc. & Shionogi Co., Ltd.
发明人： Dganit Bar , Elena Feinstein , Orit Segev
IPC分类号： A61K031/7076 , A61K031/52
CPC分类号： A61K31/13 , A61K31/155 , A61K31/16 , A61K31/275 , A61K31/52 , A61K31/70 , A61K31/7076 , G01N2333/91171
摘要： This invention provides a method for the treatment of a subject in need of treatment for osteoarthritis comprising administering to said subject an amount of an inhibitor of spermidine biosynthesis sufficient to effect a substantial inhibition of spermidine biosynthesis. This invention also provides the use of an inhibitor of spermidine biosynthesis in the treatment of a subject in need of treatment of osteoarthritis in an amount sufficient to effect a substantial inhibition of spermidine biosynthesis This invention further provides a method of preparing a therapeutic composition for the treatment of a subject in need of a treatment for osteoarthritis and the invention further provides a method identifying an inhibitor of spermidine biosynthesis, whereby the inhibitor is a spermidine synthesis inhibitor.
摘要翻译：本发明提供了治疗需要治疗骨关节炎的受试者的方法，包括向所述受试者施用足以实现亚精胺生物合成的实质性抑制的量的亚精胺生物合成抑制剂。本发明还提供了亚精胺生物合成抑制剂在治疗需要治疗骨关节炎的受试者中的用量，其量足以实现亚精胺生物合成的实质性抑制。本发明还提供了一种制备用于治疗的治疗组合物的方法需要治疗骨关节炎的受试者，本发明进一步提供鉴定亚精胺生物合成抑制剂的方法，其中抑制剂是亚精胺合成抑制剂。

6. 发明申请

US20040180336A1 Method for enrichment of natural antisense messenger RNA 失效
标题翻译：富含天然反义信使RNA的方法
公开(公告)号：US20040180336A1
公开(公告)日：2004-09-16
申请号：US09833031
申请日：2001-04-11
申请人： Quark Biotech, Inc.;
发明人： Shlomit Gilad , Paz Einat , Avital Grossman
IPC分类号： C12Q001/68 , C12P019/34
CPC分类号： C12N15/113 , C12N2330/10 , C12Q1/6809
摘要： A method for enrichment of natural antisense mRNA which involves hybridization of cDNA obtained from sense RNA with cDNA obtained from antisense RNA, followed by DNA polymerase treatment of the sense-antisense hybrid DNA molecule. A natural antisense library can be generated by cloning of sense-antisense hybrid DNA molecules in a vector.
摘要翻译：富含天然反义mRNA的方法，其涉及从有义RNA获得的cDNA与从反义RNA获得的cDNA杂交，然后进行有义反义杂交DNA分子的DNA聚合酶处理。可以通过在载体中克隆正义反义杂交DNA分子来产生天然反义文库。

7. 发明申请

US20040053301A1 Genes associated with mechanical stress, expression products therefrom, and uses thereof 失效
标题翻译：与机械应力相关的基因，表达产物及其用途
公开(公告)号：US20040053301A1
公开(公告)日：2004-03-18
申请号：US10454351
申请日：2003-06-04
申请人： QUARK BIOTECH, INC.
发明人： Paz Einat , Orit Segev , Rami Skaliter , Elena Feinstein , Alexander Faerman , Aviva Samach
IPC分类号： C12Q001/68 , C07H021/04 , C07K014/705 , C07K016/28 , C12P021/02 , C12N005/06
CPC分类号： C07H21/04 , C07K14/47 , C07K16/18
摘要： The disclosure relates to human and mechanical stress induced genes, in particular gene 608, and functional equivalents, probes therefor, tests to identify such genes, polypeptide expression products of such genes, antibodies to the polypeptides, uses for such genes, expression products and antibodies, e.g., in diagnosis (for instance risk determination), treatment, prevention, or control, of osteoporosis or fractures; and to diagnostic, treatment, prevention, or control methods or processes, as well as compositions therefor and methods or processes for making and using such compositions, and receptors therefor and methods or processes for obtaining and using such receptors.
摘要翻译：本公开涉及人和机械应激诱导的基因，特别是基因608和功能等同物，其探针，鉴定这些基因的测试，这些基因的多肽表达产物，对多肽的抗体，用于这些基因，表达产物和抗体，例如骨质疏松症或骨折的诊断（例如风险确定），治疗，预防或控制; 以及诊断，治疗，预防或控制方法或过程，以及其组合物以及用于制备和使用这些组合物及其受体的方法或方法以及用于获得和使用这些受体的方法或方法。

8. 发明申请

WO2005046564A3 DIAGNOSIS AND TREATMENT OF LIVER FIBROSIS 审中-公开
标题翻译：肝纤维化的诊断与治疗
公开(公告)号：WO2005046564A3
公开(公告)日：2005-12-15
申请号：PCT/IL2004001048
申请日：2004-11-16
申请人： QUARK BIOTECH INC , SANKYO CO , MOR ORNA , FEINSTEIN LENA , SHAPIRA HAGIT
发明人： MOR ORNA , FEINSTEIN LENA , SHAPIRA HAGIT
IPC分类号： A61K20060101 , A61K31/00 , A61K48/00 , C07H21/04 , C07K16/40 , C12N15/113 , C12Q1/68
CPC分类号： A61K31/00 , A61K2039/505 , C07K16/40 , C12N15/1137 , C12N2310/11 , C12N2310/14 , C12Y301/04004
摘要： The present invention provides methods of treatment of liver fibrosis by identification and isolation of polynucleotide sequences, the expression of which is altered in liver fibrosis. The present invention also relates to the use of these isolated polynucleotides and the polypeptides encoded thereby as probes for diagnosis, for screening of treatment modalities and as targets for modulation in liver fibrosis. In particular, the present invention provides methods, compounds and pharmaceutical compositions for the treatment of liver fibrosis. Novel pharmaceutical compositions comprising oligonucleotides or antibodies are also provided.
摘要翻译：本发明提供了通过鉴定和分离肝纤维化中表达改变的多核苷酸序列来治疗肝纤维化的方法。本发明还涉及这些分离的多核苷酸和由其编码的多肽作为探针用于诊断，筛选治疗模式和作为肝纤维化调节的靶标的用途。特别地，本发明提供了用于治疗肝纤维化的方法，化合物和药物组合物。还提供了包含寡核苷酸或抗体的新型药物组合物。

9. 发明申请

WO2005072057A2 OLIGORIBONUCLEOTIDES AND METHODS OF USE THEREOF FOR TREATMENT OF FIBROTIC CONDITIONS AND OTHER DISEASES 审中-公开
标题翻译：用于治疗纤维性疾病和其他疾病的低分子化合物及其使用方法
公开(公告)号：WO2005072057A2
公开(公告)日：2005-08-11
申请号：PCT/IL2005/000102
申请日：2005-01-27
申请人： QUARK BIOTECH, INC. , MOR, Orna , FEINSTEIN, Elena
发明人： MOR, Orna , FEINSTEIN, Elena
IPC分类号： A61K48/00 , C07H21/04 , C07K14/705 , C07K16/18 , C07K16/40 , C12N9/10 , C12N15/113 , C12Q1/68
CPC分类号： C07H21/04 , C07K16/40 , C07K2317/21 , C07K2317/76 , C12N9/1044 , C12N15/1137 , C12N2310/111 , C12N2310/14 , C12N2310/321 , C12N2310/322 , C12Y203/02013 , C12N2310/3527 , C12N2310/3521
摘要： The invention relates to a double-stranded compound, preferably an oligoribonucleotide (siRNA), which down-regulates the expression of a human TGaseII gene at the post-transcriptional level. The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the oligoribonucleotide compound, and a pharmaceutically acceptable carrier. The present invention also contemplates a method of treating a patient suffering from a fibrotic disease such as pulmonary, kidney and liver fibrosis or ocular, scarring comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient. The invention also relates to treatment of fibrotic and other diseases by use of antibodies to TGaseII polypeptide.
摘要翻译：本发明涉及在转录后水平下调人TGaseII基因表达的双链化合物，优选寡核糖核苷酸（siRNA）。本发明还涉及包含该化合物或能够表达寡核糖核苷酸化合物的载体和药学上可接受的载体的药物组合物。本发明还考虑了治疗患有纤维化疾病如肺，肾和肝纤维化或眼睛，瘢痕形成的患者的方法，其包括以治疗有效剂量向患者施用药物组合物，从而治疗患者。本发明还涉及通过使用TGaseII多肽的抗体来治疗纤维化和其它疾病。

10. 发明申请

WO2005041857A2 BONE MORPHOGENETIC PROTEIN (BMP) 2A AND USES THEREOF 审中-公开
标题翻译：骨形态蛋白（BMP）2A及其用途
公开(公告)号：WO2005041857A2
公开(公告)日：2005-05-12
申请号：PCT/IL2004/000924
申请日：2004-10-06
申请人： QUARK BIOTECH, INC. , FUJIWAWA PHARMACEUTICAL CO., LTD. , FEINSTEIN, Elena , METT, Igor , GORODIN, Svetlana , SHTUTMAN, Michael
发明人： FEINSTEIN, Elena , METT, Igor , GORODIN, Svetlana , SHTUTMAN, Michael
IPC分类号： A61K
CPC分类号： C12N15/1136 , C12N2310/11 , C12N2310/111 , C12N2310/14
摘要： The present invention provides compositions and methods for alleviation or reduction of the symptoms and signs associated with damaged neuronal tissues whether resulting from tissue trauma, or from chronic or acute degenerative changes. In particular, some embodiments of the present invention provide one or more pharmaceutical compositions comprising as an active ingredient a BMP2A inhibitor further comprising a pharmaceutically acceptable diluent or carrier. An additional embodiment provides a method for reducing damage to the central nervous system in a patient who has suffered an injury to the central nervous system, comprising administering to the patient a pharmaceutical composition in a dosage sufficient to reduce the damage. Yet another embodiment provides of the use of a BMP2A inhibitor for the preparation of a medicament for promoting or enhancing recovery in a patient who has suffered an injury to the central nervous system. Preferable inhibitors according to some embodiments of the invention are siRNA molecules and neutralizing antibodies. An additional embodiment provides a method for identifying a chemical compound that modulates apoptosis. Further, a process for diagnosing a neurodegenrative disease or an ischemic event in a subject is provided. The preferred methods, materials, and examples that will now be described are illustrative only and are not intended to be limiting; materials and methods similar or equivalent to those described herein can be used in practice or testing of the invention. Other features and advantages of the invention will be apparent from the following detailed description, and from the claims.
摘要翻译：本发明提供用于缓解或减少与损伤的神经元组织相关的症状和体征的组合物和方法，无论是由组织创伤引起的，还是由慢性或急性退行性变化引起。特别地，本发明的一些实施方案提供一种或多种药物组合物，其包含作为活性成分的进一步包含药学上可接受的稀释剂或载体的BMP2A抑制剂。另外的实施方案提供了减轻对中枢神经系统损伤的患者中的中枢神经系统的损伤的方法，包括以足以减少损伤的剂量向患者施用药物组合物。另一个实施方案提供了BMP2A抑制剂用于制备用于促进或增强患有中枢神经系统损伤的患者的恢复的药物的用途。根据本发明一些实施方案的优选的抑制剂是siRNA分子和中和抗体。另外的实施方案提供了鉴定调节凋亡的化合物的方法。此外，提供了用于诊断受试者中的神经发生性疾病或缺血事件的方法。现在将要描述的优选方法，材料和实施例仅是说明性的而不是限制性的; 可以在本发明的实践或测试中使用与本文所述类似或等同的材料和方法。从以下详细描述和权利要求书中，本发明的其它特征和优点将变得显而易见。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式